Methotrexate

Polymyositis, Uveitis, Prophylaxis against graft versus host disease + 27 more

Treatment

20 Active Studies for Methotrexate

What is Methotrexate

Methotrexate

The Generic name of this drug

Treatment Summary

Methotrexate is a medication used to reduce inflammation and control cell division in diseases like arthritis, breast cancer, and non-Hodgkin's lymphoma. It is usually used as a last resort for these conditions when other treatments have failed or the patient is intolerant. Methotrexate was approved by the FDA in 1953, and although it is effective, it can also have toxic side effects.

Methotrexate

is the brand name

image of different drug pills on a surface

Methotrexate Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Methotrexate

Methotrexate

1953

137

Effectiveness

How Methotrexate Affects Patients

Methotrexate is a drug used to reduce inflammation. It works by blocking enzymes that help cells reproduce, so it prevents cell division. Methotrexate generally needs to be taken weekly and has a narrow safety range, so it is important to not take too much or too little. It is important not to take methotrexate daily.

How Methotrexate works in the body

Methotrexate prevents cells from reproducing by blocking the enzymes that create nucleotides. It also works to reduce inflammation in rheumatoid arthritis by blocking an enzyme which leads to an accumulation of adenosine in the body, stimulating receptors and reducing inflammation.

When to interrupt dosage

The prescribed dosage of Methotrexate is contingent upon the diagnosed malady, such as Uveitis, Polymyositis and nonleukemic meningeal cancer. The amount of dosage is indicated in the table below, depending on the method of application.

Condition

Dosage

Administration

Takayasu Arteritis

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Medically induced abortion

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Acute Promyelocytic Leukemia

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Soft Tissue Sarcoma

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Chronic Graft Versus Host Disease

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Leukemia

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Arthritis, Juvenile

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Polymyositis

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Uveitis

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Chemotherapy

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Psoriasis

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Leukemia

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Lymphoma, Non-Hodgkin

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Dermatomyositis

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Multiple Sclerosis

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Breast Cancer

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Lymphoma

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Crohn's Disease

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Lupus

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Pregnancy, Ectopic

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Warnings

Methotrexate has two contraindications, meaning that it should not be taken alongside the conditions found in the following table.

Methotrexate Contraindications

Condition

Risk Level

Notes

Non Neoplastic Condition

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Methotrexate may interact with Pulse Frequency

There are 20 known major drug interactions with Methotrexate.

Common Methotrexate Drug Interactions

Drug Name

Risk Level

Description

2-Methoxyethanol

Major

The risk or severity of adverse effects can be increased when Methotrexate is combined with 2-Methoxyethanol.

9-(N-methyl-L-isoleucine)-cyclosporin A

Major

The risk or severity of adverse effects can be increased when Methotrexate is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.

Abetimus

Major

The risk or severity of adverse effects can be increased when Methotrexate is combined with Abetimus.

Acteoside

Major

The risk or severity of adverse effects can be increased when Methotrexate is combined with Acteoside.

Aldosterone

Major

The risk or severity of adverse effects can be increased when Methotrexate is combined with Aldosterone.

Methotrexate Toxicity & Overdose Risk

The lowest toxic dose of leucovorin in rats has been found to be 135mg/kg and 146mg/kg in mice. Signs of overdose include a decrease in white blood cells, platelets, and red blood cells; mouth sores; nausea and vomiting; stomach ulcers; and bleeding from the digestive tract. In case of an overdose, patients should be treated with glucarpidase, and should not be given leucovorin for 2 hours before or after receiving glucarpidase.

image of a doctor in a lab doing drug, clinical research

Methotrexate Novel Uses: Which Conditions Have a Clinical Trial Featuring Methotrexate?

764 active clinical trials are presently evaluating the potential of Methotrexate to treat Uveitis, Small Cell Lung Cancer and Soft Tissue Sarcoma.

Condition

Clinical Trials

Trial Phases

Soft Tissue Sarcoma

51 Actively Recruiting

Phase 2, Not Applicable, Phase 1, Phase 4, Early Phase 1, Phase 3

Non-Hodgkin's Lymphoma

115 Actively Recruiting

Phase 1, Phase 2, Not Applicable, Phase 3, Early Phase 1, Phase 4

Lupus

65 Actively Recruiting

Phase 2, Not Applicable, Phase 1, Phase 3, Phase 4, Early Phase 1

Bladder Cancer

101 Actively Recruiting

Phase 2, Not Applicable, Phase 1, Phase 3, Early Phase 1

Acute Lymphoblastic Leukemia

120 Actively Recruiting

Phase 1, Phase 2, Phase 3, Not Applicable, Early Phase 1, Phase 4

Multiple Sclerosis

127 Actively Recruiting

Phase 3, Not Applicable, Phase 4, Phase 2, Phase 1, Early Phase 1

Rheumatoid Arthritis

55 Actively Recruiting

Not Applicable, Phase 4, Phase 3, Phase 2, Phase 1

Hematopoietic stem cells

3 Actively Recruiting

Early Phase 1, Phase 1, Phase 2

Takayasu Arteritis

1 Actively Recruiting

Phase 2

Psoriasis

0 Actively Recruiting

Mycosis Fungoides

0 Actively Recruiting

Chemotherapy

4 Actively Recruiting

Phase 1, Phase 3, Not Applicable

Crohn's Disease

54 Actively Recruiting

Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4, Early Phase 1

Acute Promyelocytic Leukemia

0 Actively Recruiting

Breast Cancer

21 Actively Recruiting

Phase 2, Phase 1, Not Applicable

Sarcoma

0 Actively Recruiting

Lymphoma

4 Actively Recruiting

Phase 1, Phase 2

Gestational Trophoblastic Disease

0 Actively Recruiting

Pregnancy, Ectopic

0 Actively Recruiting

Polymyositis

3 Actively Recruiting

Phase 2, Phase 3

Methotrexate Reviews: What are patients saying about Methotrexate?

5

Patient Review

4/24/2022

Methotrexate for Rheumatoid Arthritis

I'm so glad we caught my RA early. I was able to start methotrexate and it put my RA into remission within three weeks. No pain and no side effects- it's been six months now!

4.3

Patient Review

9/26/2017

Methotrexate for Rheumatoid Arthritis

I felt great the first week I took this drug and it improved my mobility. However, the second week I started feeling anxious, tired, dizzy, and my skin began peeling all over. This is the second time I've tried this medication and it has had the same side effects each time.

4

Patient Review

1/4/2017

Methotrexate for Psoriasis associated with Arthritis

I have psoriatic arthritis and I haven't been treated with methotrexate, so this review might get deleted. But I would urge anyone with inflammatory arthritis to investigate food sensitivities and the "LEAP" protocol. It's helped me a lot.

4

Patient Review

4/8/2017

Methotrexate for Psoriasis associated with Arthritis

I took this to treat my psoriasis, and it did clear up quickly. However, I stopped taking it because it gave me very loose stools. Fortunately, I've had great success with using essential oils instead.

4

Patient Review

3/15/2022

Methotrexate for Psoriasis

I've been using this medication for approximately 4 weeks. My scalp psoriasis has cleared up by about 85%. I don't have the large flaking anymore, but I still have the itchiness.

4

Patient Review

8/25/2016

Methotrexate for Rheumatoid Arthritis

3

Patient Review

12/6/2017

Methotrexate for Psoriasis associated with Arthritis

I started taking this medication seven weeks ago at a dosage of 10mg per day. After four weeks, I increased my dosage to 12.5mg per day as instructed by my doctor. I have seen mixed results so far; some of my plaques are clearing up gradually, but the larger ones don't seem to be affected much yet. I haven't experienced any major side effects other than some abdominal discomfort. Additionally, while my joint pain and stiffness has not worsened (as it usually does during the winter months), neither has the swelling gone down or my joints become more functional (they're only at about 90% right now).

3

Patient Review

10/4/2017

Methotrexate for Psoriasis associated with Arthritis

I've been taking this once-a-week pill for two years now with no adverse effects. That being said, it hasn't completely stopped the inflammation caused by my psoriatic arthritis--I still have swollen and painful joints in my hands and feet. My doctor also prescribed Meloxicam for pain control, as well as D3, folic acid, and fish oil.

2.3

Patient Review

7/5/2018

Methotrexate for Rheumatoid Arthritis

I've been taking methotrexate for ten years now and I'm finding it less effective.

2.3

Patient Review

10/9/2016

Methotrexate for Rheumatoid Arthritis

No significant side effects noted, other than some balance issues.

2

Patient Review

4/3/2020

Methotrexate for Rheumatoid Arthritis

After taking this medication for two months, I experienced such shortness of breath that walking just 30 feet became a difficult task. I feel like I've ruined my lungs and now have to see a doctor in an attempt to get better.

2

Patient Review

10/3/2017

Methotrexate for Rheumatoid Arthritis

It started promising but didn't quite deliver.

1.3

Patient Review

9/13/2020

Methotrexate for Sarcoidosis

I started with the lowest possible dose and gradually increased it, but saw no change in my nerve pain. If anything, it got worse while I was on this medication.

1

Patient Review

10/11/2016

Methotrexate for Psoriasis associated with Arthritis

My mum started with a low dose of 7.5mg per week. However, after a few days she stopped eating and was constantly tired and shaky. Just three days after the second dose, she had to be hospitalized.

1

Patient Review

10/14/2018

Methotrexate for Rheumatoid Arthritis

I was on prednisone for a year and it just barely helped me get by. I switched to methotrexate, but after only two months I had to stop working because I felt worse than ever. Today I went to the ER and got an injection of prednisone so that I could function.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about methotrexate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Why is methotrexate so toxic?

"Although relatively safe, methotrexate can cause folate metabolism problems. Prescriptions as high as 25 to 30 mg per week are not unusual in modern rheumatology."

Answered by AI

Is methotrexate a high risk medication?

"Methotrexate is a dangerous drug and needs to be handled with extra care every time it is prescribed, given out, and administered, no matter what the setting, dose, or reason for use is. Although people have been seriously harmed and killed while in the hospital, many of the bad things that have happened have happened after the person left the hospital."

Answered by AI

What is methotrexate used to treat?

"Methotrexate is commonly used to treat inflammatory conditions such as rheumatoid arthritis, psoriasis, and Crohn's disease."

Answered by AI

What are the side effects of taking methotrexate?

"The following are symptoms which may indicate a health problem: feeling dizzy, feeling drowsy, having a headache, having swollen or tender gums, decreased appetite, reddened eyes, hair loss."

Answered by AI

Clinical Trials for Methotrexate

Image of Ohio State University Comprehensive Cancer Center in Columbus, United States.

Ruxolitinib for T-Cell Lymphoma

18+
All Sexes
Columbus, OH

This phase II trial tests how well ruxolitinib as a maintenance medication works to prevent relapse and graft-versus-host disease (GVHD) for patients who have undergone stem cell transplantation for T-cell lymphoma. GVHD is a common problem that may occur after a blood stem cell transplant. The "graft" is the donor blood cells that patients get during the transplant. The "host" is the person receiving the cells. GVHD is when the donor graft attacks and damages some of the transplant recipient's tissues. Ruxolitinib is a type of drug called a Janus kinase (JAK) inhibitor which works by decreasing the immune response of cells in the body. It is also a cancer growth blocker that blocks the growth factors that trigger the cancer cells to divide and grow. Ruxolitinib works by blocking a gene, called JAK2, that is important in the production of cancer cells.

Phase 2
Recruiting

Ohio State University Comprehensive Cancer Center

Jonathan Brammer, MD

Incyte Corporation

Image of University of Illinois at Chicago in Chicago, United States.

Functional Balance Intervention for Multiple Sclerosis

40 - 90
All Sexes
Chicago, IL

The study involves a two-arm, Phase 1, randomized controlled clinical trial designed to establish the feasibility and effects of a Functional Balance Intervention (FBI) on physical and cognitive function, as well as measures of daily living among persons with multiple sclerosis (PwMS). Combined Specific Aims: Aim 1: Examine the effect of the FBI (Intervention Group) on physical function in PwMS compared to a stretching program (Control Group). Hypothesis 1: After four months of training, the FBI group will show significantly greater improvements in physical function compared to the stretching group. Aim 2: Examine the effect of the multicomponent FBI on cognitive function in PwMS compared to the stretching program. Hypothesis 2: After four months of training, the FBI group will show significantly greater improvements in cognitive function compared to the stretching group. Aim 3: Examine the effects of the multicomponent FBI compared to the Control Group among PwMS on measures of daily living (dual-task performance, balance confidence, community mobility, and quality of life). Hypothesis 3: After four months of training, the FBI group will show significantly greater improvements in measures of daily living compared to the stretching group. All assessment sessions will be conducted virtually via Zoom. All measures collected during the initial screening, pre-training assessment, training progression, and mid- and post-training assessment sessions will be administered either via Zoom with a Helper Buddy present or through survey links sent to participants via the UIC REDCap system. The training sessions will be performed independently by the participants in the presence of a Helper Buddy. The investigators will recruit 75 people with multiple sclerosis (PwMS) for this study. Eligible participants will be randomized to either the FBI (Intervention) or stretching (Control) group, followed by an onboarding session with a designated Helper Buddy. Training will occur twice weekly for four months. Based on the anticipated attrition rate, the investigators aim for 40 PwMS to complete the post-training assessments and finish the study.

Recruiting
Has No Placebo

University of Illinois at Chicago

Image of National Institutes of Health Clinical Center in Bethesda, United States.

CD22 CAR T-cells for Acute Lymphoblastic Leukemia

3 - 65
All Sexes
Bethesda, MD

Background: Acute lymphoblastic leukemia (ALL) is a type of blood cancer. Chimeric antigen receptor (CAR) therapy involves taking immune cells (T cells) from a person and modifying them to better target cancer cells. CAR T-cell therapy that targets a marker called CD19 has been show to can cure ALL in many children and adults. But in about 50% of patients, the ALL comes back within a year. Researchers want to find out if a second treatment with CAR T-cell therapy that targets a different marker, CD22, can keep the cancer away longer. Objective: To see if CD22 CAR T-cell therapy can keep ALL away longer. Eligibility: People aged 3 to 65 years who have no signs of cancer after CD19 CAR T-cell treatment for ALL. Design: Participants will be screened. They will have imaging scans and tests of their heart function. A sample of tissue (biopsy) will be collected from their bone marrow. They will have a fluid sample collected from the area around their spinal cord. Participants will undergo collection of their white blood cells (T cells) during a procedure called leukapheresis. Blood will be taken from their body through a vein. The blood will pass through a machine that separates out the T cells. The remaining blood will be returned to the body through a different vein. The cells will be altered in a lab to create CD22 CAR T-cell therapy. Participants will take drugs over 4 consecutive days to prepare their body for the CAR T-cell therapy; then they will receive their modified T cells through a tube inserted into a vein. Some people may need to stay in the hospital during treatment. Participants will have follow-up visits for 2 years.

Phase 2
Waitlist Available

National Institutes of Health Clinical Center

Sara K Silbert, M.D.

Have you considered Methotrexate clinical trials?

We made a collection of clinical trials featuring Methotrexate, we think they might fit your search criteria.
Go to Trials
Image of The University of British Columbia in Vancouver, Canada.

Nutritional Therapy + Anti-TNFα for Crohn's Disease

9 - 17
All Sexes
Vancouver, Canada

Children with Crohn's disease (CD), a type of Inflammatory Bowel Disease (IBD), often face serious health challenges, including poor growth, frequent hospital stays, and long-term medication use. Although biologic drugs like infliximab, an anti-TNFα (Tumor necrosis factor α) medication, have improved treatment, they don't work for everyone: many children still experience symptoms or disease flare-ups. Nutritional therapies, especially the Crohn's Disease Exclusion Diet (CDED), may help improve treatment outcomes. This study will assess whether starting CDED at the same time as infliximab leads to better responses to treatment. The goal of this study is to improve how well children respond to therapy, reduce drug exposure, and support better long-term health.

Waitlist Available
Has No Placebo

The University of British Columbia

Kevan Jacobson, MBBCh, FRCP, FRCPC, AGAF, CAGF

Image of MUHC - Montreal General Hospital in Montreal, Canada.

Ustekinumab for Crohn's Disease and Ulcerative Colitis

18+
All Sexes
Montreal, Canada

The goal of this clinical trial is to evaluate whether disease remission can be maintained when biologic therapy is reduced in patients with Crohn"s disease (CD) and ulcerative colitis (UC) taking ustekinumab (UST). The main question it aims to answer is: Can we de-escalate UST subcutaneous dose either from every 4 weeks (Q4) to every 8 weeks (Q8) or every 8 weeks (Q8) to every 12 weeks (Q12) in CD or UC patients in deep remission without loosing their response? Researchers will follow UST blood levels, inflammation markers and intestinal mucosa integrity and to see if UST dose can be reduced while maintaining clinical remission. Participants will: Change UST dosing from Q4 to Q8 or from Q8 to Q12. Visit the clinic once every 12 weeks for checkups and tests.

Phase 4
Recruiting

MUHC - Montreal General Hospital

Janssen Inc.

Have you considered Methotrexate clinical trials?

We made a collection of clinical trials featuring Methotrexate, we think they might fit your search criteria.
Go to Trials
Image of Washington University School of Medicine in St Louis, United States.

Supplemental Imaging for Breast Cancer

25 - 55
Female
St Louis, MO

Recent research has shown that, among women with extremely dense breasts and normal results on mammogram, magnetic resonance imaging (MRI) use has significantly reduced the occurrence of breast cancer that is diagnosed during the time between two regular screening mammograms (also known as interval cancers). The investigators have developed and validated an approach to use the whole mammogram image, develop a mammogram risk score (MRS), and calibrate this to the SEER breast cancer incidence rates for US women. This model (Prognosia Breast) generates an absolute 5-year risk of breast cancer and classifies approximately 5.7% of the population as high risk using the ASCO 3% cut point as used for endocrine therapy to reduce risk. Follow-up generates an incidence of 25.2 cases per 1,000 women per year.

Waitlist Available
Has No Placebo

Washington University School of Medicine

Tabassum Ahmad, M.D.

Have you considered Methotrexate clinical trials?

We made a collection of clinical trials featuring Methotrexate, we think they might fit your search criteria.
Go to Trials